Mezigdomide, Carfilzomib, and Dexamethasone
Phase II Clinical Trial of Mezigdomide/Carfilzomib/Dexamethasone (MeziKD) in Patients With Relapsed or Refractory Multiple Myeloma (MM) With Extramedullary Disease (EMD)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 28 patients (estimated)
- Sponsors
- Roswell Park Cancer Institute
- Tags
- Cereblon E3 Ligase Modulators (CELMoDs)
- Trial Type
- Treatment
- Last Update
- 2 months ago
- SparkCures ID
- 2111
- NCT Identifier
- NCT06627751
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.